Our Portfolio
We partner with the most innovative young companies and entrepreneurs to support breakthrough therapeutics, diagnostics, and digitally-enabled healthcare to improve the practice of medicine.
Ascend is a gene-to-GMP contract development and manufacturing organization founded by Monograph in December 2021. Ascend is innovating manufacturing processes to improve quality, potency, safety, and cost, enabling better reach for gene therapy technologies. The company offers process development, clinical manufacturing, and analytical and regulatory support for biotech companies working in advanced modalities requiring flexible CMC services, through sites in Maryland, Florida, and Germany.
Autobahn is a San Diego-based, clinical-stage biotechnology company that is developing an adjunctive therapy for depressive illnesses. Autobahn’s lead molecule, ABX-002, is a potent and selective, CNS-directed thyroid hormone receptor beta (TRβ) agonist. The company is completing Phase 2 studies on therapies for people with major depressive disorder (MDD) and bipolar depression. Monograph participated in the Series C financing led by Newpath Partners in July 2024.
AviadoBio is a UK-based, clinical-stage gene therapy company focused on developing treatments for neurodegenerative diseases using novel routes of administration. The company is advancing a program to treat an inherited form of frontotemporal dementia, based on pioneering research from King's College London and the UK Dementia Research Institute. Monograph co-led the Series A financing round with NEA in November 2021, and the company entered a partnership with Japanese pharmaceutical group Astellas in 2024.
Maxion Therapeutics is a UK-based, preclinical biotechnology company developing antibody drugs against ion channels and G-protein-coupled receptors (GPCRs) using its proprietary KnotBody® technology to overcome challenges with this target class. The Seed funding round was co-led by Monograph and LifeArc Ventures alongside BGF, and the Series A was led by General Catalyst, with strategic participation from Lilly Ventures, in February 2025.
Nocion Therapeutics is a clinical-stage biotechnology company developing an inhaled small molecule therapeutic, taplucanium, with applications in conditions such as chronic cough, itch, and pain. Monograph co-led the Series B financing with Arkin Bio Capital in February 2024, the proceeds of which are being used to run a Phase 2b study in chronic cough.
Ollin Biosciences is a clinical-stage biotechnology company focused on acquiring and developing best-in-disease therapies for vision-threatening conditions, including wet age-related macular degeneration (AMD) and diabetic macular edema (DME). The company was established in 2023 and publicly launched in September 2025 with initial financing from its founders Monograph, ARCH Venture Partners and Mubadala Capital. The company recently completed the Phase 2 study of its bispecific antibody targeting VEGF and Ang2 in the treatment of AMD and DME versus Vabysmo.
ODAIA delivers a unique, AI-powered commercial insights platform that serves pharmaceutical companies. With its ability to provide near real-time and predictive perspective on the dynamic changes of the pharmaceutical marketplace, ODAIA’s proprietary platform empowers leading life science brands to more efficiently bring therapeutics to the markets that need them. Monograph co-led the company’s Series B financing in April 2023.
Ouro Medicines is a San Francisco-based biotechnology company developing immune reset therapeutics for people living with chronic autoimmune diseases. Founded by Monograph in partnership with GSK, the Series A was co-led by TPG Life Sciences Innovations, NEA, and Norwest Venture Partners in December 2024.
Prolynx is a US-based biotechnology company dedicated to developing ultra-long-acting medicines for obesity and related metabolic diseases. The company’s proprietary portfolio is built on a proven half-life extension technology engineered to support more consistent, long-term treatment with improved tolerability and optimized pharmacokinetics. The Series A financing was led by 5AM Ventures, OrbiMed, and Monograph.
Sudo is a US-based, clinical-stage neuro-immunology company with R&D leadership based in the UK. The company is advancing a pipeline of TYK2 inhibitors for debilitating and highly prevalent diseases such as multiple sclerosis and psoriasis. Monograph participated in the Series B financing round in December 2023, co-led by Enavate Sciences and TPG Life Sciences Innovation, with participation from Frazier, Sanofi Ventures, Surveyor, and Eventid
Exited
Human Immunology Biosciences (HI-Bio) is a US-based precision immunology company leveraging human genetics to deliver patient-targeted approaches to autoimmune disorders. HI-Bio is a new company that Monograph is co-incubating with Arch Venture Partners. Monograph co-led the Series A financing round in August 2021.
Exited May 2024
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences for Up to $1.8B.
MiroBio is a therapeutics company developing checkpoint agonist antibodies, a new class of therapies designed to restore immune balance and treat autoimmune disease. This work is based on 15 years of research from the University of Oxford. Monograph participated in the Series B financing round in June 2022.
Exited August 2022
Gilead Sciences to Acquire MiroBio for approx $405 million
UroGen Pharma is a US-headquartered biotech company developing and commercialising innovative solutions to treated urothelial and specialty cancers. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Monograph participated in a $120M private placement led by RA Capital and Great Point Partners which also included Acorn Bioventures and Horton Capital Partners.
Exited July 2025
Elevara Medicines is a UK-based, clinical-stage biotechnology company developing non-immunosuppressive therapies for the treatment of rheumatoid arthritis (RA) and chronic inflammatory diseases. Founded by Monograph and Weatherden in March 2025, its lead program is an oral CDK4/6 inhibitor targeting the overactive joint-lining cells that drive inflammation and damage in RA. The Series A funding was led by Forbion and Sofinnova Partners, with participation from Monograph.
RegASK is a Singapore-based global regulatory technology SaaS company enabling businesses in the biopharma, consumer health, medtech, and food industries to leverage AI to strengthen and scale their regulatory and compliance capabilities. Monograph led the Series A financing in December 2022.